Patents by Inventor Xibin Liao

Xibin Liao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DUAL GATE ARRAY SUBSTRATE AND DISPLAY PANEL
    Publication number: 20240096902
    Abstract: The dual gate array substrate of the present disclosure includes a plurality of groups of dual gate lines, a plurality of data lines, a plurality of pixel pairs and a plurality of common electrode lines, each common electrode line is arranged between two pixel units in a same pixel pair and is connected to common electrodes of the two pixel units through two first vias; a layer where the common electrode line is located and a layer where a source/drain electrode of a thin film transistor is located are different layers and insulated from each other; the two first vias are on both sides of the data line.
    Type: Application
    Filed: April 27, 2021
    Publication date: March 21, 2024
    Inventors: Cong WANG, Yingmeng MIAO, Dongchuan CHEN, Seungmin LEE, Yanping LIAO, Xibin SHAO, Jiantao LIU
  • Bruton's tyrosine kinase inhibitors
    Patent number: 11554118
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: January 17, 2023
    Assignees: SUZHOU BAIJIBUGONG PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • 6-mercaptopurine nucleoside analogues
    Patent number: 11535645
    Abstract: A compound has the following formula (I) or formula (II), an isomer thereof, a tautomer thereof, a pharmaceutical acceptable solvate thereof, or a pharmaceutical acceptable prodrug thereof.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: December 27, 2022
    Inventor: Xibin Liao
  • JAK inhibitors
    Patent number: 11365188
    Abstract: Janus kinases (JAKs) inhibitors have the following Formula (I):
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: June 21, 2022
    Inventor: Xibin Liao
  • BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20220064162
    Abstract: Bruton's tyrosine kinase (BTK) inhibitors have the following Formula (I) or (II):
    Type: Application
    Filed: January 17, 2020
    Publication date: March 3, 2022
    Inventors: Xibin LIAO, Yubin LV
  • 6-MERCAPTOPURINE NUCLEOSIDE ANALOGUES
    Publication number: 20210380628
    Abstract: A compound has the following formula (I) or formula (II), an isomer thereof, a tautomer thereof, a pharmaceutical acceptable solvate thereof, or a pharmaceutical acceptable prodrug thereof.
    Type: Application
    Filed: October 16, 2019
    Publication date: December 9, 2021
    Inventor: Xibin LIAO
  • BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20210121458
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: January 1, 2021
    Publication date: April 29, 2021
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20210107903
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: March 21, 2018
    Publication date: April 15, 2021
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • Bruton's tyrosine kinase inhibitors
    Patent number: 10933063
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: March 2, 2021
    Assignees: Suzhou Baijibugong Pharmaceutical Technology Co., Ltd.
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • JAK INHIBITORS
    Publication number: 20210053943
    Abstract: Janus kinases (JAKs) inhibitors have the following Formula (I):
    Type: Application
    Filed: March 18, 2019
    Publication date: February 25, 2021
    Inventor: Xibin LIAO
  • Bruton's tyrosine kinase inhibitors
    Patent number: 10793566
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: October 6, 2020
    Assignees: ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • Bruton's tyrosine kinase inhibitors
    Patent number: 10662187
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: May 26, 2020
    Assignees: Zibo Biopolar Changsheng Pharmaceutical Co. Ltd., Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20190275037
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: May 22, 2019
    Publication date: September 12, 2019
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20190276453
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: May 22, 2019
    Publication date: September 12, 2019
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • Bruton's tyrosine kinase inhibitors
    Patent number: 10358446
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: July 23, 2019
    Assignees: ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20190062328
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: January 17, 2017
    Publication date: February 28, 2019
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • Tetrahydro-azepinoquinolines as agonists of the 5-HTreceptor
    Patent number: 10131660
    Abstract: Certain tetrahydro-azepinoquinolines of structural formula I are agonists of the mammalian 5-HT2c receptor, and, in particular, are selective agonists of the mammalian 5-HT2c receptor. The compounds of the present invention are therefore useful for the treatment, control, or prevention of diseases, conditions, or disorders responsive to stimulation of the 5-HT2c receptor, such as obesity, obesity-related conditions, and certain CNS-related disorders, including schizophrenia and depression. They are also useful as aids for tobacco smoking cessation.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: November 20, 2018
    Assignee: Sunnylife Pharma, Inc.
    Inventors: Jonathan A. Groeper, Xibin Liao, Zhijian Lu
  • BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20180222904
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: October 3, 2016
    Publication date: August 9, 2018
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • TETRAHYDRO-AZEPINOQUINOLINES AS AGONISTS OF THE 5-HT2C RECEPTOR
    Publication number: 20180215752
    Abstract: Certain tetrahydro-azepinoquinolines of structural formula I are agonists of the mammalian 5-HT2c receptor, and, in particular, are selective agonists of the mammalian 5-HT2c receptor. The compounds of the present invention are therefore useful for the treatment, control, or prevention of diseases, conditions, or disorders responsive to stimulation of the 5-HT2c receptor, such as obesity, obesity-related conditions, and certain CNS-related disorders, including schizophrenia and depression. They are also useful as aids for tobacco smoking cessation.
    Type: Application
    Filed: August 26, 2015
    Publication date: August 2, 2018
    Applicant: Sunnylife Pharma, Inc.
    Inventors: Jonathan A. Groeper, Xibin Liao, Zhijian Lu
  • Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
    Patent number: 9649294
    Abstract: Glucagon receptor antagonist compounds are disclosed which are of long duration of action. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: May 16, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Libo Xu, Emma R. Parmee, Xibin Liao